List Free, Shop Smart, Save Gas!
register | sign in

Price: 10.00

ALK Fusion Probe

For Sale By Healthcarebio@aliyun.com   -   Fuel Cost:
Zip Code:
ALK Gene Fusion Detection ProbeProduct Advantages: 1.Fleetness: Tissue probe hybridization time: 2 hours. Cell probe hybridization time: 1 hour.2.Accuracy: Less non-specific background staining (dyeing). Increase difficult samples detection rate.3.Reproducibility: Different laboratories test results are highly reproducibleProduct Description :Lung cancer,Website:http://www.health-carebiotech.com, Anaplastic large cell lymphomaAbout ALKThe ALK gene encodes a transmembrane receptor tyrosine kinase (RTK). The ALK-NPM1 fusion protein was originally found in anaplastic large cell lymphoma and in other tumors including neuroblastoma and non-small cell lung cancer. The gene was found to be mutated, amplified, or rearranged, with chromosome rearrangements being the most common, resulting in ALK fusion with other genes including ALK (chromosome 2)/EML4 (chromosome 2), ALK/RANBP2 (chromosome 2), ALK/ATIC (chromosome 2), ALK/TFG (chromosome 3) , ALK / NPM1 (chromosome 5), ALK / SQSTM1 (chromosome 5), ALK / KIF5B (chromosome 10), ALK/CLTC (chromosome 17), ALK/TPM4 (chromosome 19), and ALK/MSN (X chromosome). Probe DescriptionALK gene break apart probe uses orange labeled dye ALK gene (3 ' End) 2p23.2 region, and a green dye ALK gene (5' End) to mark 2p23.1-p23.2 region. ALK gene break apart probe can detect all ALK gene rearrangement, avoiding missed diagnosis caused by a single fusion gene (such as EML4-ALK). The 2013 edition of China anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer diagnosis expert consensus pointed out that adenocarcinoma, for age (60 years old), nonsmoking, EGFR, KRAS, HER2 or P53 in patients without NSCLC gene mutations, ALK gene positive rate is high as 30%~ 42%. Pathological studies suggest that the positive rate in signet-ring cell-containing mucinous or solid adenocarcinoma is higher than other types of lung adenocarcinoma. In 2013, CFDA approved XALKORI (Crizotinib) for targeted therapy of advanced ALK-positive non-small cell lung cancer, and the necessary condition for XALKORI (Crizotinib) drug treatment was FISH for the detection of ALK-positive non-small cell lung cancer. ALK-positive gene fusion patients are sensitive to XALKORI (Crizotinib) treatment.  Size SpecificationsReferences :l  Rodig SJ, et al. (2009) Clin Cancer Res 15: 5216-23.l  Sasaki T, et al. (2010) Eur J Cancer 46: 1773-80.l  Von Laffert M, et al. (2013) Lung Cancer 81: 200-6.
ALK Fusion Probe,Fluorescence In-situ Hybridization Probes



Share |

Healthcarebio@aliyun.com's Reviews

by:
on:
relationship:
score:
review:
Me
07/16/2019
Ad Viewer
5
My Review

Related Ads




 

© Copyright  2001 - 2020 ADBIRDS Design & Market Inc.  All Rights Reserved.


We are the free online classified advertising site designed to make a positive difference in our world.  With affordable business services and a unique distance - fuel cost calculator when you select "get distance".  Our goal is to help you save time and fuel while shopping and dining at local businesses.  All images and information uploaded by adbirds are property of adbirds or used with permission.   Please, help us remain child - friendly!  Log in to flag an ad that seems inappropriate.  Please read our Privacy Policy and the Terms and Conditions/ User Agreement prior to posting.  We reserve the right to modify terms without notice.  ADBIRDS is not responsible for the actions or performance of any advertiser herein.     




Site Map